Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Pronova BioPharma ASA (OSL:PRON) 22 August, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") today announces that it has entered into a sourcing agreement with an undisclosed third party manufacturer for the supply of intermediaries for the manufacture of Active Pharmaceutical Ingredients (APIs). The sourcing agreement will enable increased manufactured volumes of APIs in excess of earlier communicated volumes for 2009.
The third party manufacturer will supply high quality cGMP manufactured intermediaries. As a result, Pronova BioPharma's revised estimate of total annual production volumes is 1 400 - 1 500 tonnes of API in 2009. The increased volumes are expected to be realised in Q3 and Q4 2009.
Tomas Settevik, Chief Executive Officer of Pronova BioPharma, commented:
"The sourcing of high quality intermediaries will further optimize our manufacturing processes. The expected increase in production volumes for 2009 is important for Pronova BioPharma to meet growing demand for our products around the world."
-- Ends --
For further information, please contact:
Hilde Steineger, Head of IR +47 48 00 42 40 Tomas Settevik, CEO +47 22 53 48 61
